Indemnification AgreementIndemnification Agreement • October 3rd, 2022 • Yumanity Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (this “Agreement”) is made as of [Date], by and between Kineta, Inc., a Delaware corporation (the “Company”), and [Indemnitee Name] (“Indemnitee”).
ContractYumanity Therapeutics, Inc. • October 3rd, 2022 • Pharmaceutical preparations • Washington
THIS WARRANT AND THE SECURITIES ISSUABLE UPON THE EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT REGISTRATION IS NOT REQUIRED.
EMPLOYMENT AGREEMENTEmployment Agreement • October 3rd, 2022 • Yumanity Therapeutics, Inc. • Pharmaceutical preparations • Washington
This Amended and Restated Employment Agreement (the “Agreement”) between you (referred to hereinafter as the “Executive”) and Kineta, Inc., a Washington corporation (the “Company”) sets forth the terms and conditions that shall govern Executive’s continued employment with the Company (referred to hereinafter as “Employment” or the “Employment Period”), effective as of the Effective Time, as such term is defined in that certain Agreement and Plan of Merger dated June 5, 2022 (the “Merger Agreement”) by and among the Company, Yumanity Therapeutics, Inc. (“Parent”) and Yacht Merger Sub, Inc. (the “Effective Date”). This Agreement amends, restates and replaces in its entirety the employment agreement entered into by and between Executive and the Company dated February 3, 2020 (the “Prior Agreement”).
KINETA, INC. COMMON STOCK PURCHASE AGREEMENTCommon Stock Purchase Agreement • October 3rd, 2022 • Yumanity Therapeutics, Inc. • Pharmaceutical preparations • Washington
This Common Stock Purchase Agreement (the “Agreement”) is made as of June 26, 2008 by and between Kineta, Inc., a Washington corporation (the “Company”), and Shawn Iadonato (“Purchaser”).
OPTION AND LICENSE AGREEMENTOption and License Agreement • October 3rd, 2022 • Yumanity Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Option and License Agreement (the “Agreement”) is made and entered into effective as of August 10, 2020 (the “Effective Date”), by and between GigaGen, Inc., a Delaware corporation (“GigaGen”), having a place of business at 1 Tower Place, Suite 750, South San Francisco, CA 94080, and Kineta, Inc., a Washington corporation (“Kineta”), having a place of business at 219 Terry Avenue North, Suite 300, Seattle, WA 98109. GigaGen and Kineta are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
EXCLUSIVE OPTION AND LICENSE AGREEMENT BETWEEN KINETA CHRONIC PAIN, LLC AND GENENTECH, INC. AS OF APRIL 11, 2018Exclusive Option and License Agreement • October 3rd, 2022 • Yumanity Therapeutics, Inc. • Pharmaceutical preparations • California
DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENTDevelopment and Manufacturing Services Agreement • October 3rd, 2022 • Yumanity Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT is made on November 22, 2019 (the “Effective Date”) by and between Kineta Chronic Pain, LLC, a Washington limited liability company with offices at 219 Terry Avenue North, Suite 300, Seattle, WA 98109 (“COMPANY” or “Kineta”) and AmbioPharm, Inc., a California corporation with an office at 1024 Dittman Court, North Augusta, SC 29842, (“AmbioPharm”).
KINETA, INC. COMMON STOCK PURCHASE AGREEMENTCommon Stock Purchase Agreement • October 3rd, 2022 • Yumanity Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS COMMON STOCK PURCHASE AGREEMENT (this “Agreement”), is made as of is made as of May 27, 2021, by and among Kineta, Inc., a Washington corporation (the “Company”) and the investor listed on Exhibit A attached to this Agreement (the “Purchaser”).
MASTER DEVELOPMENT SERVICES AGREEMENTMaster Development Services Agreement • October 3rd, 2022 • Yumanity Therapeutics, Inc. • Pharmaceutical preparations • New York
This Master Development Services Agreement (this “MDSA”) is made and entered into as of the date of last signature below (the “Effective Date”) by and between Kineta, Inc., a Washington corporation having its principal place of business at 219 Terry Avenue North, Suite 300, Seattle, WA 98109 (“Client”), and Samsung Biologics Co., Ltd., a Korean corporation having its principal place of business at 300, Songdo bio-daero, Yeonsu-gu, Incheon, 21987, Republic of Korea (“SBL”). Client and SBL are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
FIRST AMENDMENT TO THE EXCLUSIVE OPTION AND LICENSE AGREEMENTOption and License Agreement • October 3rd, 2022 • Yumanity Therapeutics, Inc. • Pharmaceutical preparations
THIS FIRST AMENDMENT TO THE EXCLUSIVE OPTION AND LICENSE AGREEMENT (the “1st Amendment”) is made effective as of November 27, 2019 (the “1st Amendment Effective Date”), between Kineta Chronic Pain, LLC, having a principal place of business at 219 Terry Avenue North, Suite 300, Seattle, Washington, 98109 (“Kineta”), and Genentech, Inc., having a principal place of business at 1 DNA Way, South San Francisco, California 94080 (“GNE”), and its Affiliates (collectively with GNE, the “Licensee”). Kineta and Licensee are each referred to herein individually as a “Party” and collectively as the “Parties”.
AMENDMENT NO. 1 TO NON-VOTING COMMON STOCK PURCHASE WARRANTYumanity Therapeutics, Inc. • October 3rd, 2022 • Pharmaceutical preparations • Washington
THIS AMENDMENT NO. 1 TO NON-VOTING COMMON PURCHASE WARRANT (the “Amendment”), effective as of March 31, 2020, is by and between Kineta, Inc. (“Kineta”) and Whetstone Ventures, LLC (“Holder”). All capitalized terms used and not otherwise defined herein shall have the meanings ascribed to them in the Warrant (as defined below).
AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • October 3rd, 2022 • Yumanity Therapeutics, Inc. • Pharmaceutical preparations • Utah
THIS AMENDED AND RESTATED EXCLUSIVE LICENSE Agreement (“Agreement”) is entered into this 28th day of July, 2020 (the “Amendment Effective Date”) by and between the UNIVERSITY OF UTAH RESEARCH FOUNDATION, a Utah non-profit corporation, having its principal place of business at 615 Arapeen Drive, Suite 310, Salt Lake City, UT 84108, hereinafter referred to as “Licensor,” and Kineta Chronic Pain, LLC, having its principal place of business at 219 Terry Avenue North, Ste. 300, Seattle, WA 98109, hereinafter referred to as “Licensee.”
FIRST AMENDMENT TO AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENTFirst Amendment • October 3rd, 2022 • Yumanity Therapeutics, Inc. • Pharmaceutical preparations
This First Amendment (the “Agreement Amendment”) is made as of December 16, 2020 (“Amendment Effective Date”), by and between the University of Utah Research Foundation, having its principal place of business at 615 Arapeen Drive, Suite 310, Salt Lake City, UT 84108 (“Licensor”), and Kineta Chronic Pain, LLC, having its principal place of business at 219 Terry Avenue North, Ste. 300, Seattle, WA 98109 (“Licensee”).
FIRST AMENDMENT TO OPTION AND LICENSE AGREEMENTOption and License Agreement • October 3rd, 2022 • Yumanity Therapeutics, Inc. • Pharmaceutical preparations
This First Amendment to Option and License Agreement (the “Amendment”), effective as of November 19, 2020 (the “First Amendment Effective Date”) by and between GigaGen, Inc., a Delaware corporation having a place of business at 1 Tower Place, Suite 750, South San Francisco, CA 94080 (“GigaGen”) and Kineta, Inc., a Washington corporation having a place of business at 219 Terry Avenue North, Suite 300, Seattle, WA 98109 (“Kineta”), amends that certain Option and License Agreement, dated August 10, 2020 by and between GigaGen and Kineta (the “Agreement”). Each of GigaGen and Kineta shall be referred to herein individually as a “Party” and collectively as the “Parties”. Capitalized terms not defined herein shall have the same meanings as set forth in the Agreement.
FIRST AMENDMENT TO OPTION AND LICENSE AGREEMENTOption and License Agreement • October 3rd, 2022 • Yumanity Therapeutics, Inc. • Pharmaceutical preparations
This First Amendment to Option and License Agreement (the “Amendment”), effective as of July 31, 2022 (the “First Amendment Effective Date”) by and between GigaGen, Inc., a Delaware corporation having a place of business at 1 Tower Place, Suite 750, South San Francisco, CA 94080 (“GigaGen”) and Kineta, Inc., a Washington corporation having a place of business at 219 Terry Avenue North, Suite 300, Seattle, WA 98109 (“Kineta”), amends that certain Option and License Agreement, dated June 9, 2021 by and between GigaGen and Kineta (the “Agreement”). Each of GigaGen and Kineta shall be referred to herein individually as a “Party” and collectively as the “Parties”. Capitalized terms not defined herein shall have the same meanings as set forth in the Agreement.
AMENDMENT NO. 1 TO ASSET PURCHASE AGREEMENTAsset Purchase Agreement • October 3rd, 2022 • Yumanity Therapeutics, Inc. • Pharmaceutical preparations • New York
This Amendment No. 1 (the “Amendment”) is dated as of December 3, 2021 and is entered by and between Kineta Viral Hemorrhagic Fever, LLC, a Washington limited liability corporation formerly known as Kineta Four, LLC (the “Purchaser”), Kineta, Inc., a Washington corporation (the “Parent”) and SIGA Technologies Inc., a Delaware corporation (“Seller”, and together with Purchaser and Parent, the “Parties”, and each, a “Party”).
ASSET PURCHASE AGREEMENTAsset Purchase Agreement • October 3rd, 2022 • Yumanity Therapeutics, Inc. • Pharmaceutical preparations • New York
This Asset Purchase Agreement (the “Agreement”) is entered into as of August 14, 2014 (the “Effective Date”), by Kineta Four, LLC, a Washington limited liability company (the “Purchaser”), and SIGA Technologies Inc., a Delaware corporation (collectively, the “Seller”). Purchaser and Seller may be individually referred to as a “Party” or collectively as the “Parties”. Certain capitalized terms used in this Agreement are defined in Exhibit A hereof.
SECOND AMENDMENT TO THE EXCLUSIVE OPTION AND LICENSE AGREEMENTOption and License Agreement • October 3rd, 2022 • Yumanity Therapeutics, Inc. • Pharmaceutical preparations
THIS SECOND AMENDMENT TO THE EXCLUSIVE OPTION AND LICENSE AGREEMENT (the “2nd Amendment”) is made effective as of October 1, 2020 (the “2nd Amendment Effective Date”), between Kineta Chronic Pain, LLC, having a principal place of business at 219 Terry Avenue North, Suite 300, Seattle, Washington, 98109 (“Kineta”), and Genentech, Inc., having a principal place of business at 1 DNA Way, South San Francisco, California 94080 (“GNE”), and its Affiliates (collectively with GNE, the “Licensee”). Kineta and Licensee are each referred to herein individually as a “Party” and collectively as the “Parties”.
